title: [Clinical study of ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer].
abstract: BACKGROUND
  To evaluate the efficacy and toxicity of ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer.
  
  
  METHODS
  Fifty-six patients with advanced non-small cell lung cancer were treated by combination chemotherapy of ifosfamide and cisplatin for two cycles: ifosfamide 1.5-2.0g/m² iv drip on day 1-4, mesna 400mg iv at 0,4,8 hours after using ifosfamide; DDP 25-30mg/m² iv drip on day 5-7. The response, toxicity, relievable period and survival period were evaluated.
  
  
  RESULTS
  The total response rate was 50.0%. The response rate of patients in primary treatment was 52.8% and that of return cases was 45.0% (P > 0.05). The median relievable period was five months. The median duration of survival (MDS) was nine months. The major toxicity was inhibition of bone marrow, especially of leukocyte and platelet.
  
  
  CONCLUSIONS
  Combination chemotherapy of ifosfamide and cisplatin is effective in the treatment of advanced non-small cell lung cancer including the return cases, and the toxicity is tolerable. If G-CSF is used as a complementary therapy, this regimen could be quite clinically valuable.
authors.affiliation: Department of Respiratory Diseases, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi 030013, P.R.China.
authors.forename: Fucai
authors.initials: F
authors.lastname: Han
authors.forename: Weihua
authors.initials: W
authors.lastname: Yang
authors.forename: Haibo
authors.initials: H
authors.lastname: Zhu
authors.forename: Qinxiang
authors.initials: Q
authors.lastname: Guo
authors.forename: Wei
authors.initials: W
authors.lastname: Guo
authors.forename: Hua
authors.initials: H
authors.lastname: Zhou